<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>Science | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <meta
    name="description"
    content="Scientific foundations of LiquidMammo™, a microRNA-based supplemental screening test designed to complement mammography."
  />

  <!-- Stylesheet -->
  assets/css/styles.css

  <!-- Favicon -->
  favicon.png
</head>

<body>

<!-- ======================================
     MINIMAL HEADER (← Home)
======================================= -->
<header class="container">
  <nav>
    index.html← Home</a>
  </nav>
</header>


<!-- ======================================
     MAIN CONTENT
======================================= -->
<main class="container">

  <h1>The Science Behind LiquidMammo™</h1>

  <!-- Overview -->
  <section class="section-tight">
    <p>
      LiquidMammo™ is built on circulating <strong>microRNA biology</strong> — a molecular signal that
      can reveal early cancer‑associated dysregulation. Unlike imaging, which detects structural
      changes, microRNA signatures reflect underlying tumor biology and may appear earlier in the
      cancer development process.
    </p>

    <p class="notice" style="margin-top:14px;">
      LiquidMammo is being developed as a
      <strong>CLIA Laboratory Developed Test (LDT)</strong>. It is not yet FDA‑cleared or FDA‑approved.
    </p>
  </section>


  <!-- microRNA fundamentals -->
  <section class="panel-light section-tight">
    <h2>What are microRNAs?</h2>

    <ul class="list-tight">
      <li>Small non‑coding RNA molecules that regulate gene expression.</li>
      <li>Involved in proliferation, immune signaling, DNA repair, metabolism, and metastasis.</li>
      <li>Stable in blood due to packaging in vesicles or protein complexes.</li>
      <li>Dysregulation patterns differ between healthy and cancer‑associated tissues.</li>
      <li>Detectable through blood‑based molecular assays.</li>
    </ul>
  </section>


  <!-- Molecular rationale -->
  <section class="section-tight">
    <h2>Why microRNA testing supports screening</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:16px;">

      <div class="card-mini">
        <h4>Early biological changes</h4>
        <p class="small">
          MicroRNA dysregulation can appear before nodules, asymmetries, or density patterns are
          visible on mammography.
        </p>
      </div>

      <div class="card-mini">
        <h4>Dense‑breast consistency</h4>
        <p class="small">
          Biological signal is not limited by breast density, providing value where imaging
          performance decreases.
        </p>
      </div>

      <div class="card-mini">
        <h4>Complementary to imaging</h4>
        <p class="small">
          Biology + imaging adds strength to screening workflows, especially in young or dense‑breast
          patients.
        </p>
      </div>

    </div>
  </section>


  <!-- The multi-marker panel -->
  <section class="panel-light section-tight">
    <h2>The LiquidMammo multi‑marker panel</h2>

    <p>
      LiquidMammo evaluates a proprietary set of microRNAs associated with tumor biology. The panel
      incorporates markers linked to:
    </p>

    <ul class="list-tight" style="margin-top:10px;">
      <li>Cell‑cycle regulation</li>
      <li>Immune microenvironment signaling</li>
      <li>Angiogenesis and stromal remodeling</li>
      <li>Apoptosis and oncogenic stress</li>
      <li>Subtype‑related expression patterns</li>
    </ul>
  </section>


  <!-- Analytics -->
  <section class="section-tight">
    <h2>Analytical approach</h2>

    <ul class="list-tight">
      <li>Standardized pre‑analytical blood processing workflow.</li>
      <li>RNA extraction and quality control under validated SOPs.</li>
      <li>Quantitative measurement of microRNA abundance.</li>
      <li>Machine‑learning classification using reference distributions.</li>
      <li>Density‑aware interpretation to contextualize risk.</li>
    </ul>
  </section>


  <!-- Use cases -->
  <section class="panel-light section-tight">
    <h2>Where the test adds value</h2>

    <ul class="list-tight">
      <li>Triaging ambiguous or equivocal imaging findings.</li>
      <li>Supporting decision‑making for dense‑breast patients.</li>
      <li>Strengthening screening confidence between imaging visits.</li>
      <li>Providing a biological layer for patients who defer mammography.</li>
    </ul>
  </section>


  <!-- Limitations -->
  <section class="section-tight">
    <h2>Limitations</h2>

    <p class="small">
      LiquidMammo is a supplemental test and does not replace mammography, MRI, ultrasound, or a
      complete clinical evaluation. All screening results should be interpreted alongside clinical
      history, imaging, and provider judgement.
    </p>
  </section>

</main>


<!-- ======================================
     FOOTER
======================================= -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC,
        and operates out of LabCentral in Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end; text-align:right;">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br/>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy & Compliance</a> •
    contact.htmlContact</a>
  </div>
</footer>

</body>
</html>





